Azithromycin Plus Hydroxychloroquine for COVID-19 Infection

NCT ID: NCT05026801

Last Updated: 2021-10-28

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-08
• Study Completion Date: 2021-08-26

Brief Summary

This is a randomized, double-blinded, Phase 3, multi-center trial of the clinical and microbiologic response of patients with a respiratory tract infection (RTI) due to coronavirus treated with a combination of azithromycin and hydroxychloroquine.

Approximately 200 patients with symptoms of an RTI who test positive for SARS-CoV-2 by polymerase chain reaction (PCR) will receive a combination of azithromycin 500 mg and hydroxychloroquine 600 mg or matching placebos for six consecutive days. There will be two treatment regimens into which patients are randomized so that all patients will receive some active therapy.

Detailed Description

As of March 22, 2020, a total of 311,988 people worldwide have been diagnosed with a respiratory infection caused by SARS-CoV-2 of whom 13,407 have died. In the United States 26,747 patients have tested positive of whom 340 have died. There is at present no established therapy for this infection. After the SARS epidemic in 2002, investigations identified chloroquine as a possible inhibitor of replication of this coronavirus. When the SARS-CoV-2 epidemic started in December of 2019, clinicians began to use chloroquine in an attempt to control the infection in newly diagnosed patients. Investigators from China reported chloroquine phosphate has apparent efficacy in treatment of pneumonia due to SARS-CoV-2. Following this report, investigators in France initiated an open label study of hydroxychloroquine, with the addition of azithromycin, in a small number of subjects with SARS-CoV-2 infection. Relative to no treatment the investigators identified a significant reduction in viral isolation by PCR in the nasal swabs of treated patients, with an additional effect seen when patients were also given azithromycin. Azithromycin, like chloroquine, is a weak base that concentrates in endosomes and lysosomes and raises the pH in those vesicles. It is possible that azithromycin and chloroquine's effect on endosomal processing reduces the inflammatory response by affecting TLR4 signaling through the endosomes.

Conditions

Respiratory Tract Infection Viral

Keywords

Coronavirus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Azithromycin plus hydroxychloroquine

Azithromycin 500 mg plus hydroxychloroquine 600 mg by mouth daily for six consecutive days

Group Type: ACTIVE_COMPARATOR

Azithromycin plus hydroxychloroquine

Intervention Type: DRUG

All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.

Placebo

Placebo

Group Type: PLACEBO_COMPARATOR

Azithromycin plus hydroxychloroquine

Intervention Type: DRUG

All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.

Interventions

Azithromycin plus hydroxychloroquine

All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.

Intervention Type: DRUG

Other Intervention Names

Placebo

Eligibility Criteria

Inclusion Criteria

1. Adults ≥18 years of age

2. History of a respiratory tract infection (RTI) for more than one but less than six days including two or more of the following signs and symptoms of an RTI:

• Fever (T ≥ 38.0 C, 100.5 F), cough, sputum production, arthralgia/myalgia, anosmia/ageusia or difficulty breathing.

3. A nasal or throat swab or nasal wash positive by PCR for SARS-CoV-2.

4. Has given written informed consent to participate in the study. Due to the public health issues related to this viral infection, witnessed informed consent may be obtained remotely.

Exclusion Criteria

1. Patients likely, in the opinion of the investigator, to require hospitalization within 48 hours of randomization into the study.

2. Concurrent use of non-study antibacterial drug therapy that would have a potential effect on outcome evaluations in patients with an RTI

3. Concurrent use of any other medications for the purpose of treating a viral infection such as influenza antivirals

4. Inability to swallow oral medication in tablet form

5. Patient has severe chronic kidney disease, or is receiving hemodialysis, or peritoneal dialysis or had a renal transplant

6. Patient is known to have severe neutropenia

7. Patients with a known prolongation of the QT interval or are taking medications which could prolong the QT interval

8. Patient is known to be pregnant

9. Patients with a known history of myasthenia gravis

10. Patients with a history of allergy to azithromycin, hydroxychloroquine or chloroquine

11. Patient is considered unlikely to survive the study period or has a rapidly progressive or terminal illness, including septic shock, associated with a high risk of mortality

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Waterbury Hospital

UNKNOWN

Sponsor Role: collaborator

Iterum Therapeutics, International Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Dunne, MD

Role: PRINCIPAL_INVESTIGATOR

Iterum Therapeutics

Locations

Waterbury Hospial

Waterbury, Connecticut, United States

Countries

United States

Other Identifiers

IT005-501

Identifier Type: -

Identifier Source: org_study_id